Siddhartha Das-Frontline

More stories by this author

At the SRM Medical Hospital at Kattankulathur in Chengalpattu district, Tamil Nadu, on August 6. It was one of several institutions across India that were tasked with carrying out phase II human clinical trials of Covaxin, the coronavirus vaccine indigenously developed by Hyderabad’s Bharat Biotech in collaboration with the ICMR.

COVID-19 patients are being treated with drugs such as itolizumab even though there is insufficient evidence on their efficacy against the disease

Some pharma companies appear to be using the ongoing pandemic as an excuse to bypass some of the necessary steps to get government approvals so that t

Divya Trivedi, Siddhartha Das ,Venkitesh Ramakrishnan